Leonard Green & Partners L.P. Sells 1,769,864 Shares of Catalent, Inc. (NYSE:CTLT)

Leonard Green & Partners L.P. lowered its position in shares of Catalent, Inc. (NYSE:CTLT) by 45.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,096,181 shares of the company’s stock after selling 1,769,864 shares during the quarter. Catalent accounts for 2.5% of Leonard Green & Partners L.P.’s investment portfolio, making the stock its 6th largest holding. Leonard Green & Partners L.P. owned 1.16% of Catalent worth $117,868,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in CTLT. Millennium Management LLC raised its position in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after acquiring an additional 2,299,784 shares in the last quarter. MBB Public Markets I LLC acquired a new position in shares of Catalent during the 2nd quarter worth $788,000. APG Asset Management N.V. increased its holdings in shares of Catalent by 26.8% in the 2nd quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock valued at $8,157,000 after purchasing an additional 32,900 shares in the last quarter. APG Asset Management US Inc. lifted its stake in shares of Catalent by 2.3% in the second quarter. APG Asset Management US Inc. now owns 52,861 shares of the company’s stock valued at $2,969,000 after purchasing an additional 1,172 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Catalent by 7.6% in the second quarter. AQR Capital Management LLC now owns 10,675 shares of the company’s stock valued at $600,000 after purchasing an additional 750 shares during the period.

Insider Buying and Selling at Catalent

In related news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock worth $782,923 over the last ninety days. Company insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.7 %

Shares of Catalent stock opened at $60.29 on Friday. The company has a market capitalization of $10.91 billion, a PE ratio of -9.88, a P/E/G ratio of 2.32 and a beta of 1.15. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. The business has a 50-day moving average of $59.64 and a 200-day moving average of $57.31.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. As a group, equities analysts forecast that Catalent, Inc. will post 0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the subject of a number of research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday. StockNews.com started coverage on Catalent in a research report on Thursday. They issued a “sell” rating for the company. Barclays boosted their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat.com, Catalent presently has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.